|
Leukocyte-Derived Nanoparticles to Treat Triple-Negative Breast Cancer
This invention is an engineered biomimetic lipid-based nanoparticle (NP) functionalized with leukocyte membrane proteins (a.k.a. leukosomes) which are capable of targeting vascular inflammation. The ratio at which these leukocyte proteins are integrated within the NP shell dictates the biological behavior of the leukosomes. This particular formulation...
Published: 10/2/2024
|
Inventor(s): Francesca Taraballi, Assaf Zinger
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Research Area > Nanomedicine, Technology Classifications > Therapeutic > Drug Delivery, Technology Classifications > Therapeutic > Nanovesicles
|
|
Beclin 2-Functionalized Therapies for Treatment of Neurodegenerative Disease and Cancer
This invention identified that Beclin 2 functions as a negative regulator of the ERK1/2 signaling, NF-κB signaling, and inflammasome activation. Furthermore, these studies demonstrated that Beclin 2 targets key signalling kinases for degradation through an ATG9A-dependent autophagic pathway. These new findings have uncovered an important role...
Published: 9/13/2024
|
Inventor(s): Rongfu Wang, Helen (Yicheng) Wang, Motao Zhu
Keywords(s):
Category(s): Clinical Area > Cancer, Clinical Area > Neurology, Research Area > Cancer, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Immunotherapy
|
|
Specific PD-1 DNA Aptamers as Immunotherapeutic Agents in the Treatment of Cancers
The invention are therapeutic PD-1 DNA aptamers used to block PD-1 activity and enhance T-cell cytotoxicity against leukemias and solid tumors. Stage of Development In vitro data: Several aptamers were developed using SELEX technology against endogenous immunoprecipitated PD-1 and they were found to have highly conserved regions using high throughput...
Published: 3/12/2024
|
Inventor(s): Swaminathan Iyer, Santhana Thankgavelu Devaraj
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Therapeutic > Immunotherapy
|
|
Microfibrillar-associated Protein 5 (MFAP5)-Specific Monoclonal Antibodies as Therapeutic Agents in Ovarian and Pancreatic Cancers
The invention are therapeutic monoclonal antibodies directed against microfibrillar-associated fibroblast-derived secreted protein 5 (MFAP-5) for the treatment of ovarian and pancreatic cancer. Cancer associated fibroblasts (CAFs) in the tumor stromal microenvironment exhibit altered secretion of extracellular proteins, which modify the tumor environment...
Published: 10/1/2024
|
Inventor(s): Stephen Wong, Jianting Sheng, Tsz Lun Yeung, Sze Lee Cecilia Leung, Samuel Mok
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Therapeutic > Antibodies
|
|
Aptamer-engineered Natural Killer Cells for Adaptive Immunotherapy
The invention is a unique technology to engineer Natural Killer (NK) cells with synthetic oligonucleotide aptamers for tumor cell-specific cancer immunotherapy. Stage of Development In vitro Study: The aptamer-engineered NK (ApEn-NK) cells could be generated via a simple one-step process in minutes. The generated ApEn-NK cells were able to specifically...
Published: 10/7/2024
|
Inventor(s): Youli Zu
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
|
Implantable therapeutic vaccine for the sustained long-term treatment and prevention of tumors and cancer (Nanolymph)
Description of InventionThe invention is a device consists of an immunostimulatory implant designed for the local recruitment and activation of immune cells against cancer. The system utilizes nanoporous membranes which allows for the sustained elution of immune adjuvants from transcutaneously refillable reservoirs embedded in the structure. With diffusion...
Published: 3/12/2024
|
Inventor(s): Alessandro Grattoni, Ying Chua
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Medical Device > Implantables, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
|
IRF4-Targeted Therapies for Cancer, Transplant Rejection, and Autoimmune Disorders
This invention is a method of depleting or over-expressing the transcription factor, interferon regulatory factor 4 (IRF4), in T cells as therapeutic strategy for conditions which are highly regulated by the immune system. The inventors have established that IRF4 represses PD-1, Helios, and other molecules associated with T cell function, representing...
Published: 10/8/2024
|
Inventor(s): Wenhao Chen, Xian Li
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Transplantation, Clinical Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Research Area > Cancer, Research Area > Immunobiology and Inflammation
|
|
Glycolytic Modulators for Therapeutic Regulation of Cell Fate
This invention is a glycolysis enhancement strategy using glycolytic modulators to improve cell fate transitions. Applied topically, systemically, or in combination with a biocompatible scaffold, the glycolytic enhancers are expected to improve wound healing, vascularity, and tissue regeneration as well as reduce fibrosis. In another application, a...
Published: 3/12/2024
|
Inventor(s): John Cooke, Li Lai
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Research Area > Regenerative Medicine, Clinical Area > Cancer, Research Area > Cancer
|
|
SREBP2 Inhibitors for Treating T-Cell Acute Lymphoblastic Leukemia
This invention is a method of inhibiting sterol regulatory element-binding protein 2 (SREBP2) in order to treat, prevent, reverse, and/or ameliorate conditions associated with an improper number of hematopoietic stem and progenitor cells (HSPCs). SREBP22 is traditionally known as a transcription factor that plays a role in cholesterol homeostasis. However,...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Qilin Gu
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
|
PSMA-Targeted CAR-T Therapy for Castration-Resistant Prostate Cancer
This invention includes ten novel PSMA-targeted CAR-T therapies to treat castration-resistant prostate cancer. The CAR-T constructs were generated using scFvs from five different mouse hybridomas. We have further enhanced the lead PSMA-targeted CAR-T therapy by co-expressing IRF4 to regulate effector T cell activity and tissue infiltration. The co-expression...
Published: 10/1/2024
|
Inventor(s): Bin He
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
